The standard therapy for differentiated thyroid carcinoma is surgery and RAI therapy is postoperatively considered for patients with distant metastasis. Pathological lesions generally develop slowly, even when RAI therapy is not effective. In contrast, although the number is very small, there are patients with progressive pathological lesions that are difficult to control. This CQ examines the effectiveness of chemotherapy for these patients.
Public Health Adverse Effect United States Retrospective Study Distant Metastasis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access
Matuszczyk A, Petersenn S, Bockisch A et al (2008) Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–213 (RS)PubMedCrossRefGoogle Scholar
Droz JP, Schlumberger M, Rougier P et al (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480–483 (RS)PubMedGoogle Scholar
Shimaoka K, Schoenfeld DA, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160 (RCT)PubMedCrossRefGoogle Scholar
Argiris A, Agarwala SS, Karamouzis MV et al (2008) A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 26:183–188 (RS)PubMedCrossRefGoogle Scholar
Leaf AN, Wolf BC, Kirkwood JM et al (2000) Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol 17:47–51 (PS)PubMedCrossRefGoogle Scholar